Visceral fat is one of the more dangerous types of fat. Fortunately, visceral fat can easily be treated and even be removed, and recently, a drink has proven to be able to reduce the visceral fat.
Express reports that black tea has been proven in helping reduce the visceral fat found in the abdominal cavity. Black tea is a kind of tea that has gone through many oxidation processes compared to other kinds of tea. A study was conducted regarding the benefits of this tea, with 111 people taking part. The participants had to drink three cups of black tea every day for a period of three months.
At the end of the study, the participants experienced a significant weight loss as well as a smaller waistline compared to drinking a weight loss beverage that also contains caffeine. Other researchers believe that this is because black tea is high on flavone - a kind of plant pigment with antioxidant properties.
It bears noting that black tea is also generally known by many to help in weight loss. Green tea is also popularly known to aid in overall weight loss as well, reducing the visceral fat.
Another study involved 2,280 adults in a timeframe of 14 years also found that those who consumed high-flavone food and drinks have a lower body mass index compared to those who did not. All in all, regularly drinking green and/or black tea can help promote overall weight loss.
Visceral fat is mostly caused by poor lifestyle choices, the diet being the main one. This is why a good diet and regular exercise can help get rid of the fat while shedding pounds. It is highly advised to cut down or steer clear of alcoholic beverages, sugar-sweetened drinks like sodas as well as fruit juices - however, fruit juices can still be advised due to their vitamin contents, it is all down to how much fruit juice can be consumed every day and being mindful of the sugar content in the juices.
As far as diets are concerned, one of the most effective diets in getting rid of visceral fat is the ketogenic or keto diet.


Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Trump Signs Order to Cut Routine Childhood Vaccines
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 



